MediWound Ltd. Q2 2025 Earnings Recap

MDWD Q2 2025 August 14, 2025

Get alerts when MDWD reports next quarter

MediWound reported a strong second quarter with a 43% sequential revenue growth, propelled by NexoBrid's increasing market adoption and significant progress on the EscharEx VALUE Phase III trial.

Earnings Per Share Miss

$-1.23 vs $-0.55 est.

-123.6% surprise

Revenue Miss

5708000 vs 6562500 est.

-13.0% surprise

Market Reaction

1-Day -0.96%

5-Day -7.47%

30-Day -10.72%

See MDWD alongside your other holdings

Add to your portfolio — free

Key Takeaways

Revenue reached $5.7 million, marking a 43% increase from Q1 2025 and a year-over-year rise from $5.1 million.
NexoBrid achieved 52% year-over-year revenue growth in the U.S., indicating expanding market penetration and customer base.
Gross profit improved to $1.3 million, reflecting a healthier revenue mix and operational efficiencies.
Increased R&D investments of $3.5 million focus on advancing the EscharEx Phase III study.
The company is on track for key manufacturing scale-up milestones by year-end, supported by substantial non-dilutive funding of $18.2 million from the U.S. Department of Defense.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit MDWD on AllInvestView.

Next Q3 2025